Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChan, Lie Sen
dc.contributor.authorDaruwalla, Jurstineen
dc.contributor.authorChristophi, Christopheren
dc.identifier.citationANZ Journal of Surgery; 78(11): 955-67en
dc.description.abstractSelective targeting of the tumour vasculature in the treatment of solid organ malignancies is an alternative to conventional chemotherapy treatment. As the tumour progressively increases in size, angiogenesis or the formation of new vasculature is essential to maintain the tumour's continual growth and survival. Therefore disrupting this angiogenic process or targeting the neovasculature can potentially hinder or prevent further tumour expansion. Many anti angiogenic agents have been investigated with many currently in clinical trials and exhibiting varied results. Vascular disrupting agents such as the Combretastatins and OXi 4503 have shown promising preclinical results and are currently being examined in clinical trials.en
dc.subject.otherAngiogenesis Inhibitors.therapeutic useen
dc.subject.otherNeoplasms.blood supply.drug therapyen
dc.subject.otherNeovascularization, Pathologic.prevention & controlen
dc.titleSelective targeting of the tumour vasculature.en
dc.typeJournal Articleen
dc.identifier.journaltitleANZ Journal of Surgeryen
dc.identifier.affiliationDepartment of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.